Aging is not inevitable decay but a process of epigenetic markers moving to the wrong positions on our DNA, causing cells to malfunction. New science shows these 'switches' can be reset using specific proteins, effectively reversing the aging process in cells and making them young again.

Individuals have unique aging trajectories for different organs. By measuring organ-specific proteins in the blood, scientists can determine if your heart is aging faster than your brain, for example. This "age gap" is a strong predictor of future disease in that specific organ.

Major pharmaceutical companies are entering the longevity sector not through dedicated anti-aging discovery programs, but by measuring biological aging biomarkers in existing metabolic programs. Unreleased trial data from Eli Lilly and Novo Nordisk demonstrated that approved GLP-1 drugs, such as semaglutide and tirzepatide, reversed biological age by three to four years on epigenetic and proteomic clocks.

The composition of proteins in blood changes so dramatically with age that it can accurately predict a person's age. Crucially, these blood-borne factors are not just passive markers; they actively influence how cells and organs function, acting as a form of internal medicine.

Biotech companies do not need regulators to recognize aging itself as a disease to gain drug approvals. According to Alex Zhavoronkov, a viable regulatory path involves conducting traditional clinical trials for specific diseases while using secondary biomarker outcome measures, such as proteomic aging clocks, to evaluate and validate a drug's gerotherapeutic longevity benefits.

While genomics predicts lifelong risk, Regeneron was surprised to discover that proteomics provides a more powerful, dynamic snapshot of health. In many cases, an individual's proteome was more effective at predicting disease outcomes in the next one to five years than their inherited genome, prompting massive investment in the technology.

By auditing the "noise" or corruption in a cell's epigenetic settings, scientists can determine a biological age. This "epigenetic clock" is a better indicator of true health than birth date, revealing that a 40-year-old could have the biology of a 30-year-old.

The next frontier in aging diagnostics is measuring the age of individual cell types from blood proteins. The biological age of specific cells, like astrocytes or muscle cells, is a much stronger predictor for diseases like Alzheimer's and ALS than the age of the whole organ.

Regeneron views genomics as a "blueprint" for long-term risk. In contrast, proteomics acts as a real-time "sensor" of the body's current state. Their research showed proteomic data was surprisingly more predictive than genetics for the near-term onset of hundreds of diseases, including cancer and heart disease.